ArticleJournal of the American College of Cardiology2019
Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays.
Article in Journal of the American College of Cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04687111 (A Randomised, Controlled, Double-blind, Double-dummy, Clinical Trial Comparing Sacubitril-Valsartan Versus Valsartan in Asymptomatic, Stage A/B HFpEF Patients With Elevated Natriuretic Peptide and Abnormal LAVI.), which is not on this map. Cited by 68 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomised, Controlled, Double-blind, Double-dummy, Clinical Trial Comparing Sacubitril-Valsartan Versus Valsartan in Asymptomatic, Stage A/B HFpEF Patients With Elevated Natriuretic Peptide and Abnormal LAVI. (Previously NCT02682719)
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it, 122 citations in OpenAlex.
- Association Between Cardiac Natriuretic Peptides and Lipid Profile: a Systematic Review and Meta-Analysis.Scientific reports · 2019Pooled it
- Cardiac biomarkers response under angiotensin receptor-neprilysin inhibitor: a sub-analysis of the NATRIUM-HF study.ESC heart failure · 2026Trial
- Effect of sacubitril/valsartan on brain natriuretic peptide level and prognosis of acute cerebral infarction.PloS one · 2023Trial
- Sacubitril/valsartan improves cardiac function in Chinese patients with heart failure: a real-world study.ESC heart failure · 2021Trial
- Intensive Lifestyle Intervention Increases Plasma Midregional Proatrial Natriuretic Peptide Concentrations in Overweight Children.Journal of the American Heart Association · 2021Trial
- Natriuretic peptide receptor C in cardiovascular-kidney-liver-metabolic syndrome: from natriuretic peptide deficiency to direct tissue signaling?Reviews in endocrine & metabolic disorders · 2026Review
- Impact of treatment strategies incorporating sacubitril/valsartan on achievement of guideline-recommended blood pressure targets and representative safety outcomes.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Pediatric heart failure in the era of cardio-immunology: inflammatory-immune context phenotypes, diagnosis, and targeted management.Frontiers in immunology · 2026Review
- Atrial Natriuretic Peptide at Discharge as a Predictive Marker for Early Rehospitalization in Patients With Heart Failure With Preserved Ejection Fraction.Journal of the American Heart Association · 2025Article
- Inhibiting atrial natriuretic peptide clearance reduces myocardial fibrosis and improves cardiac function in diabetic rats.European heart journal open · 2025Article
- Responses of B-type natriuretic peptide (BNP), mature BNP and proBNP to sacubitril/valsartan differs between responders and non-responders.Open heart · 2025Article
- Saudi Heart Association Position Statement on NT-proBNP for Cardiovascular Risk Screening in Asymptomatic Adults With Type 2 Diabetes Mellitus.Journal of the Saudi Heart Association · 2025Article
- Biomarkers of Hemodynamic Congestion in Heart Failure.Current heart failure reports · 2024Review
- Emerging Role of Natriuretic Peptides in Diabetes Care: A Brief Review of Pertinent Recent Literature.Diagnostics (Basel, Switzerland) · 2024Review
- Possible role of LCZ696 in atherosclerosis: new inroads and perspective.Molecular and cellular biochemistry · 2024Review
- Effects of angiotensin receptor-neprilysin inhibitor on ketone body metabolism in pre-heart failure/heart failure patients.Scientific reports · 2024Article
- Association of natriuretic peptides and receptor activity with cardio-metabolic health at middle age.Scientific reports · 2024Article
- Role of NT-proBNP and lung ultrasound in diagnosing and classifying heart failure in a hospitalized oldest-old population: a cross-sectional study.BMC geriatrics · 2024Article
- Predictive biomarkers for the early detection and management of heart failure.Heart failure reviews · 2024Review
- Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure With Preserved Ejection Fraction.Circulation. Heart failure · 2024Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWith sacubitril/valsartan treatment, B-type natriuretic peptide (BNP) concentrations increase; it remains unclear whether change in BNP concentrations is similar across all assays for its measurement. Effects of sacubitril/valsartan on atrial natriuretic peptide (ANP) concentrations in patients are unknown. Lastly, the impact of neprilysin inhibition on mid-regional pro-ANP (MR-proANP), N-terminal pro-BNP (NT-proBNP), proBNP
objectivesThis study sought to examine the effects of sacubitril/valsartan on results from different natriuretic peptide assays.
methodsTwenty-three consecutive stable patients with heart failure and reduced ejection fraction were initiated and titrated on sacubitril/valsartan. Change in ANP, MR-proANP, BNP (using 5 assays), NT-proBNP (3 assays), proBNP
resultsAverage time to 3 follow-up visits was 22, 46, and 84 days. ANP rapidly and substantially increased with initiation and titration of sacubitril/valsartan, more than doubling by the first follow-up visit (+105.8%). Magnitude of ANP increase was greatest in those with concentrations above the median at baseline (+188%) compared with those with lower baseline concentrations (+44%); ANP increases were sustained. Treatment with sacubitril/valsartan led to inconsistent changes in BNP, which varied across methods assessed. Concentrations of MR-proANP, NT-proBNP, and proBNP
conclusionsInitiation and titration of sacubitril/valsartan led to variable changes in concentrations of multiple natriuretic peptides. These results provide important insights into the effects of sacubitril/valsartan treatment on individual patient results, and further suggest the benefit of neprilysin inhibition may be partially mediated by increased ANP concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.